236 related articles for article (PubMed ID: 33902424)
1. Immunotherapy for Breast Cancer Treatment: Current Evidence and Therapeutic Options.
Singh K; Yadav D; Jain M; Singh PK; Jin JO
Endocr Metab Immune Disord Drug Targets; 2022; 22(2):212-224. PubMed ID: 33902424
[TBL] [Abstract][Full Text] [Related]
2. Breast Cancer Vaccines: New Insights.
Benedetti R; Dell'Aversana C; Giorgio C; Astorri R; Altucci L
Front Endocrinol (Lausanne); 2017; 8():270. PubMed ID: 29081765
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.
Krasniqi E; Barchiesi G; Pizzuti L; Mazzotta M; Venuti A; Maugeri-Saccà M; Sanguineti G; Massimiani G; Sergi D; Carpano S; Marchetti P; Tomao S; Gamucci T; De Maria R; Tomao F; Natoli C; Tinari N; Ciliberto G; Barba M; Vici P
J Hematol Oncol; 2019 Oct; 12(1):111. PubMed ID: 31665051
[TBL] [Abstract][Full Text] [Related]
4. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
5. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
7. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
[TBL] [Abstract][Full Text] [Related]
8. Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going.
Schettini F; Buono G; Cardalesi C; Desideri I; De Placido S; Del Mastro L
Cancer Treat Rev; 2016 May; 46():20-6. PubMed ID: 27057657
[TBL] [Abstract][Full Text] [Related]
9. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines.
Sanchez K; Page D; McArthur HL
Curr Probl Cancer; 2016; 40(2-4):151-162. PubMed ID: 27855963
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancer.
Kearney MR; McGuinness JE; Kalinsky K
Breast Cancer Res Treat; 2021 Aug; 189(1):1-13. PubMed ID: 34213658
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer.
De La Cruz LM; Czerniecki BJ
Ann Surg Oncol; 2018 Oct; 25(10):2852-2857. PubMed ID: 30014455
[TBL] [Abstract][Full Text] [Related]
13. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.
Arab A; Yazdian-Robati R; Behravan J
Arch Immunol Ther Exp (Warsz); 2020 Jan; 68(1):2. PubMed ID: 31915932
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint Inhibitors in the Treatment of Breast Cancer.
Lyons TG; Dickler MN; Comen EE
Curr Oncol Rep; 2018 Apr; 20(7):51. PubMed ID: 29713831
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in Breast Cancer: When, How, and What Challenges?
Henriques B; Mendes F; Martins D
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829916
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
17. Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis.
Eng J; Thibault G; Luoh SW; Gray JW; Chang YH; Chin K
Methods Mol Biol; 2020; 2055():521-562. PubMed ID: 31502168
[TBL] [Abstract][Full Text] [Related]
18. Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018).
Cottu P; Coudert B; Perol D; Doly A; Manson J; Aujoulat O; Barletta H; Chalabi N; Samelson L; Pivot X
Eur J Cancer; 2020 Dec; 141():209-217. PubMed ID: 33176232
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches.
Ayoub NM; Al-Shami KM; Yaghan RJ
Breast Cancer (Dove Med Press); 2019; 11():53-69. PubMed ID: 30697064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
